Summary
Terrance P. Coyne, who serves as Executive Vice President and Chief Financial Officer of Royalty Pharma plc (NASDAQ: RPRX), sold a total of 34,791 Class A ordinary shares on March 23, 2026. The disposition was executed under a pre-established 10b5-1 trading plan and produced aggregate proceeds of approximately $1.58 million.
Details of the sale
The shares were transacted at a weighted average price of $45.5287. Individual trades in the block ranged from $45.30 to $45.94 per share. Of the shares sold, 32,916 were disposed of indirectly through TPC RP 2021, LLC, while 1,875 were sold indirectly through TPC RP EPA1 LLC.
Post-transaction holdings
After the March 23 transactions, Coyne's indirect and direct holdings are recorded as follows: 65,832 shares indirectly held through TPC RP 2021, LLC; 43,886 shares indirectly held through TPC RP EPA1 LLC; 24,170 shares held by a Spouse's IRA; 23,270 shares held in an IRA; 1,500 shares held directly; and 1,450 shares held by a Spouse.
Market context
Royalty Pharma's shares are trading close to a 52-week high of $47.86. Over the past six months the stock has returned 32 percent. Separate analysis from InvestingPro indicates that, on its metrics, the stock currently appears overvalued relative to its Fair Value. The InvestingPro platform is cited as offering additional metrics and ProTips for investors evaluating the company.
Corporate developments
In related corporate activity, Royalty Pharma agreed to provide $250 million to Zymeworks Inc. via a non-recourse royalty-backed note financing. The repayment structure for that financing is tied to 30 percent of worldwide tiered royalties on Ziihera, with Zymeworks retaining 70 percent of the royalties while repayments are in effect.
Royalty Pharma has also made several senior appointments. Lucas Glass was named Head of Artificial Intelligence to bolster the company's AI capabilities. Greg Butz was appointed Executive Vice President of Partnering & Investments; his background includes service at Bank of America. Kenneth Sun will lead the firm's expansion in Asia as Senior Vice President and Head of Asia, following his tenure at Morgan Stanley.
How these items sit together
The reported insider sale by the company's CFO, the equity's near-term market strength, the financing transaction with Zymeworks, and the set of executive hires are presented here as discrete disclosures and developments. The filings and company announcements specify the financial terms and the new leadership roles as described above.
Methodology note
The sale reported for Coyne was recorded on a Form 4 filing with the Securities and Exchange Commission and executed under a pre-arranged 10b5-1 trading plan. The financing arrangement with Zymeworks is described as non-recourse and royalty-backed, with repayment mechanics detailed in the company's announcement.
Key facts at a glance
- Insider sale: 34,791 Class A ordinary shares sold on March 23, 2026 under a 10b5-1 plan.
- Proceeds and prices: Approximately $1.58 million in proceeds; weighted average price $45.5287; trade range $45.30 to $45.94.
- Financing and hires: $250 million non-recourse royalty-backed note to Zymeworks; Lucas Glass, Greg Butz, and Kenneth Sun appointed to senior roles.